The wholly-owned subsidiary of Apichope Pharmaceutical Group Co.,Ltd. (ASX: 300723), Guangzhou Apichope Pharmaceutical Co., Ltd., has recently received the Drug Registration Certificate for Procaterol Hydrochloride Oral Solution, approved and issued by the National Medical Products Administration.
This pharmaceutical product is intended for the relief of symptoms such as breathing difficulties caused by respiratory obstructive disorders associated with the following diseases: bronchial asthma, chronic bronchitis, acute bronchitis, and asthmatic bronchitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments